Food Allergy Treatment Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The global food allergy treatment market encompasses pharmaceuticals, biologics, and over-the-counter therapies for diagnosing, preventing, and managing adverse immune reactions to specific foods. With an estimated global value of approximately $7.4 billion in 2025, the market is experiencing sustained expansion as new therapeutic options become available and diagnosis rates climb. Growth is supported by increased healthcare attention to allergy-related conditions, regulatory approvals for novel treatments, and rising patient demand for interventions that reduce reaction severity beyond strict dietary avoidance.

• •Encompasses oral immunotherapy, biologics, epinephrine auto-injectors, and diagnostic products
• •Estimated global market value of approximately $7.4 billion in 2025
• •Projected annual growth rate of approximately 8.3% through the early 2030s

Rising prevalence of food allergies globally, particularly in pediatric populations, is the fundamental driver of market expansion. The introduction and commercialization of disease-modifying therapies such as oral immunotherapy have shifted treatment paradigms from strict avoidance to active management. Supporting factors include improved diagnostic techniques, increased public awareness of allergy risks, and growing demand from patients and caregivers for preventive treatment options.

• •Increasing prevalence of IgE-mediated food allergies, especially to peanuts, tree nuts, and shellfish
• •Regulatory approvals for oral immunotherapy products since 2020 have expanded treatment availability
• •Greater investment in allergy research and clinical trials for novel therapeutic candidates

The market is commonly segmented by allergen type, product type, route of administration, and geographic region. Allergens such as peanuts, tree nuts, dairy, shellfish, and wheat each constitute distinct treatment segments, with peanut allergy representing the largest revenue contributor due to its high prevalence and severity. Regionally, North America leads in market share due to high diagnosis rates and early adoption of novel therapies, while Europe and the Asia-Pacific region are expanding as healthcare systems improve allergy recognition and treatment access.

• •Peanut allergy treatment commands the largest share among allergen-specific segments
• •North America accounts for the dominant regional market share
• •Asia-Pacific is projected as the fastest-growing regional segment through the early 2030s

What are the recent trends and outlook?

The pipeline is characterized by innovation in long-term immunotherapy approaches, biologics targeting specific immune pathways, and digital health integration. Multi-allergen immunotherapy protocols and combination therapies are under active investigation to address the complexity of patients with multiple food sensitivities. Healthcare providers and payers are increasingly focusing on quality-of-life outcomes and cost-effectiveness, which will shape reimbursement and adoption patterns as the market matures through 2030 and beyond.

• •Biologics targeting immune pathways implicated in allergic reactions are in advanced clinical development
• •Digital health platforms for allergy tracking and exposure management are being integrated into treatment regimens
• •Research into combination immunotherapy approaches for patients with multiple concurrent food allergies is expanding